Other Events ·
Immuron Limited filed a Form 6-K to report that CEO Steven Lydeamore presented at the Emerging Growth Conference in…
IMRNImmuron Ltd
Immuron Limited filed a Form 6-K to report that CEO Steven Lydeamore presented at the Emerging Growth Conference in Melbourne on August 19, 2026. The presentation highlighted FY2026 global sales revenue of A$7.7 million, up 6% year-over-year, with strong growth in Australia and the U.S. The company announced a strategic reset to partner its clinical assets IMM-124E and IMM-529 for development and commercialization to reduce cash burn and unlock value through licensing fees and milestones. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.